ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 269 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2024. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $110,850,851 | -16.7% | 2,697,101 | -5.4% | 0.01% | -16.7% |
Q1 2024 | $133,124,863 | -14.4% | 2,851,250 | -12.3% | 0.01% | -25.0% |
Q4 2023 | $155,534,646 | +69.9% | 3,252,502 | +26.7% | 0.01% | +60.0% |
Q3 2023 | $91,544,138 | -19.5% | 2,567,858 | +4.2% | 0.01% | -16.7% |
Q2 2023 | $113,731,209 | +3.3% | 2,465,450 | -10.2% | 0.01% | 0.0% |
Q1 2023 | $110,102,546 | -59.6% | 2,745,707 | -53.3% | 0.01% | -25.0% |
Q4 2022 | $272,676,790 | +157.3% | 5,885,534 | +129.9% | 0.01% | +14.3% |
Q3 2022 | $105,991,000 | -27.7% | 2,559,544 | +4.2% | 0.01% | -22.2% |
Q2 2022 | $146,603,000 | +3.6% | 2,457,308 | +26.1% | 0.01% | +28.6% |
Q1 2022 | $141,513,000 | +0.2% | 1,948,684 | +16.1% | 0.01% | 0.0% |
Q4 2021 | $141,174,000 | +6.2% | 1,678,841 | +13.9% | 0.01% | 0.0% |
Q3 2021 | $132,928,000 | +1.7% | 1,473,865 | +7.5% | 0.01% | 0.0% |
Q2 2021 | $130,713,000 | -28.7% | 1,370,875 | -14.9% | 0.01% | -36.4% |
Q1 2021 | $183,410,000 | -21.0% | 1,610,839 | -3.9% | 0.01% | -21.4% |
Q4 2020 | $232,050,000 | +55.4% | 1,676,299 | -7.7% | 0.01% | +40.0% |
Q3 2020 | $149,339,000 | -3.5% | 1,816,992 | -8.2% | 0.01% | -9.1% |
Q2 2020 | $154,738,000 | +56.2% | 1,978,244 | -11.3% | 0.01% | +22.2% |
Q1 2020 | $99,050,000 | +5.5% | 2,229,351 | +1.4% | 0.01% | +50.0% |
Q4 2019 | $93,908,000 | +4.0% | 2,198,747 | +4.2% | 0.01% | -14.3% |
Q3 2019 | $90,304,000 | -32.9% | 2,110,888 | -0.4% | 0.01% | -30.0% |
Q2 2019 | $134,603,000 | +1.0% | 2,119,732 | +10.3% | 0.01% | 0.0% |
Q1 2019 | $133,290,000 | +49.4% | 1,921,711 | -6.3% | 0.01% | +25.0% |
Q4 2018 | $89,205,000 | -31.8% | 2,051,639 | +19.8% | 0.01% | -20.0% |
Q3 2018 | $130,735,000 | +3.2% | 1,712,524 | +3.9% | 0.01% | -9.1% |
Q2 2018 | $126,736,000 | +23.2% | 1,648,751 | -18.3% | 0.01% | +22.2% |
Q1 2018 | $102,864,000 | +38.9% | 2,017,295 | +26.4% | 0.01% | +50.0% |
Q4 2017 | $74,050,000 | -8.2% | 1,596,519 | +5.4% | 0.01% | -14.3% |
Q3 2017 | $80,689,000 | -15.4% | 1,515,071 | -1.4% | 0.01% | -12.5% |
Q2 2017 | $95,417,000 | +11.2% | 1,536,285 | +21.4% | 0.01% | 0.0% |
Q1 2017 | $85,784,000 | -12.7% | 1,265,556 | -9.4% | 0.01% | -11.1% |
Q4 2016 | $98,227,000 | -6.3% | 1,397,189 | -5.4% | 0.01% | -18.2% |
Q3 2016 | $104,807,000 | +68.9% | 1,477,436 | +16.5% | 0.01% | +57.1% |
Q2 2016 | $62,048,000 | -23.7% | 1,268,686 | -1.2% | 0.01% | -22.2% |
Q1 2016 | $81,315,000 | -26.3% | 1,284,324 | +30.6% | 0.01% | -25.0% |
Q4 2015 | $110,321,000 | +33.7% | 983,423 | +14.8% | 0.01% | +20.0% |
Q3 2015 | $82,525,000 | -3.7% | 856,881 | +2.4% | 0.01% | +11.1% |
Q2 2015 | $85,705,000 | +165.5% | 837,050 | +61.0% | 0.01% | +200.0% |
Q1 2015 | $32,285,000 | +39.9% | 519,987 | -1.1% | 0.00% | +50.0% |
Q4 2014 | $23,072,000 | +7.6% | 525,781 | +38.8% | 0.00% | 0.0% |
Q3 2014 | $21,445,000 | +420.5% | 378,865 | +312.4% | 0.00% | – |
Q2 2014 | $4,120,000 | +31.6% | 91,870 | +43.6% | 0.00% | – |
Q1 2014 | $3,131,000 | – | 63,981 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |